Pharming Group N.V.
Pharming Group N.V. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Leniolisib for Immune Dysregulation in PIDs on November 15, 2026. There are 6 upcoming events on record.
Pharming Group N.V. generates cash from operations, so a burn-based runway figure does not apply.
Across 15 concluded trials, 80% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 15, 2026 | Leniolisib for Immune Dysregulation in PIDs | Trial Milestone | Phase 2 |
| November 30, 2026 | Pediatric Patients Aged 4 to 11 Years With APDS | Trial Milestone | Phase 3 |
| October 15, 2027 | Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | Trial Milestone | Phase 2 |
| July 9, 2028 | Pediatric Patients Aged 1 to 6 Years With APDS | Trial Milestone | Phase 3 |
| March 31, 2029 | Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease | Trial Milestone | Phase 2 |
| August 12, 2029 | Long-term Safety and Efficacy of Leniolisib in PIDs With Immune Dysregulation | Trial Milestone | Phase 2 |
Track PHAR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open PHAR in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.